RxDoctor Payments Data

Arturo Perez, MD

General Practice · Miami, FLNPI 1558516765

Payments from drug & device makers

$5,505in general payments, 2019–2025

Across 134 payments — averaging $41.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$1K
  • AstraZeneca$1K
  • GSK$743
  • Biosense Webster, Inc.$235
  • Boehringer Ingelheim$154
  • plus $299 from 4 others

What the payments were for

  • Travel & lodging$78014%
  • Food & beverage$4,28378%
  • Education$4428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,505 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$3,713
Medicare patients
12
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$71,974
LinzessLinaclotide75$56,003
FarxigaDapagliflozin Propanediol50$43,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$38,304
JanuviaSitagliptin Phosphate34$37,736
TrulicityDulaglutide23$31,386
OzempicSemaglutide32$29,901
JardianceEmpagliflozin17$25,339
TradjentaLinagliptin23$17,929
XareltoRivaroxaban11$14,770
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,640
SymbicortBudesonide/Formoterol Fumarate29$9,253
Tadalafil48$8,833
Diclofenac Sodium390$7,888
Albuterol Sulfate HfaAlbuterol Sulfate179$4,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,121$63,53696 claims
Boehringer IngelheimJardiance, Tradjenta$154$43,26840 claims
GSKTrelegy Ellipta$743$38,30450 claims
Novo NordiskOzempic$22$29,90132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →